

ASX Release Stock Code: PRR

Friday, 19 September 2008

### **SALE OF UNMARKETABLE PARCELS COMPLETED**

Australian cancer treatment development company Prima BioMed (Prima) is pleased to announce that the sale of unmarketable parcels of the company's shares has been successfully completed.

The clean up of the unmarketable parcels of small numbers of Prima shares has been one of the company's corporate objectives in 2008, and it is pleased to have completed the process.

The sale of the unmarketable parcels was executed by broking house Tolhurst Ltd.

Cheques for shareholders who were part of the unmarketable parcels will be mailed by 13 October 2008.

ENDS

#### **For further information please contact:**

Mr Martin Rogers

Director

Prima BioMed

Ph: 02 9232 4420, 0428 268 357

E: [martin.rogeres@primabiomed.com.au](mailto:martin.rogeres@primabiomed.com.au)

James Moses

Partner

Fortbridge Consulting

Ph: 0420 991 574

E: [james.moses@fortbridge.com](mailto:james.moses@fortbridge.com)

Website: [www.primabiomed.com.au](http://www.primabiomed.com.au)

#### **About Prima BioMed**

Prima BioMed is an Australian biotechnology company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology. Prima's lead product, CVac™ has completed Phase IIa clinical development in Ovarian Cancer and is working to a path of US FDA IND approval.

#### **About CVac™ Ovarian Cancer Treatment**

CVac™ is Prima's lead product. It is of key importance as there is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate. CVac™ is a maintenance therapy administered post-surgery and post-chemotherapy to delay relapse and control metastases.

There are currently no products available as maintenance based therapies for ovarian cancer and the global market for ovarian cancer therapeutics was valued at US\$2.1b in 2007 and is expected to total US\$3.6b by 2010.

Regulatory approval of CVac™ over the next 6-9 months is the core focus for Prima.

For further information, visit [www.primabiomed.com.au](http://www.primabiomed.com.au)

*This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing and results of clinical trials, interpretation and implications of such results, availability or adequacy of financing, the sales and marketing of commercial products or the efficacy of products. Although the Company believes that the forward - looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward - looking statements are expressly qualified in their entirety by this cautionary statement.*

**Prima BioMed Ltd, Suite 1705, 109 Pitt St, Sydney NSW 2000 AUSTRALIA**

[www.primabiomed.com.au](http://www.primabiomed.com.au) Ph:+61 2 9232 4420 Fax:+61 2 9232 4450

ABN: 90 009 237 889